Abstract:RRP is caused by HPV infection of the aerodigestive tract that significantly impacts quality‐of‐life including the ability to communicate and breathe. This study aims to determine whether rationale exists for combination therapeutic approaches using VEGF inhibitors and/or immune checkpoint blockade. Our analysis shows that RRP tissue shows elevated levels of multiple immune check point targets and VEGFR3, with varied patterns unique to each papilloma patient. Some of these immune checkpoint markers already have novel immunotherapies available or in development, providing molecular rationale to offer these systemic treatments to selected patients affected by RRP alongside VEGF inhibitors. Objectives Recurrent respiratory papillomatosis (RRP) is caused by human papilloma virus (HPV) infection of the aerodigestive tract that significantly impacts quality‐of‐life including the ability to communicate and breathe. Treatment was traditionally limited to serial ablative procedures in the O.R. with possible local adjuvant therapy, but new systemic therapies, such as Vascular endothelial growth factor (VEGF) inhibitors, are showing significant promise. This study aims to determine whether rationale exists for combination therapeutic approaches using VEGF inhibitors and/or immune checkpoint blockade. Methods Using fresh specimens from the O.R., we performed flow cytometry on papilloma, normal adjacent tissue, and blood. Papilloma and surrounding tissue were examined for expression of PD‐L1, PD‐L2, Galectin‐9, VEGFR2, and VEGFR3. CD8+ and CD4+ T cells were assayed for expression of PD‐1, TIGIT, LAG3, and TIM3. Results Our data shows that papilloma tissue exhibits significantly higher levels of PD‐L1 and PD‐L2 compared to adjacent tissue. Elevated levels of the VEGF receptor VEGFR3 were also observed in papilloma tissue. When examining T cells within the papilloma, elevated PD‐1 and TIGIT expression was observed on CD8+ T cells, while levels of PD‐1, TIGIT, and TIM3 were elevated on CD4+ T cells compared to PBMCs. Heterogenous marker expression was observed between individuals. Conclusions Our analysis shows that RRP tissue shows elevated levels of multiple immune check point targets and VEGFR3, with varied patterns unique to each papilloma patient. Some of these immune checkpoint markers already have novel immunotherapies available or in development, providing molecular rationale to offer these systemic treatments to selected patients affected by RRP alongside VEGF inhibitors. Laryngoscope, 2024

[Primary study on glycan structure in pathopoiesis mechanism of recurrent respiratory papillomatosis].

The Preliminary Study on Mechanism of Immunological Evasion in Recurrent Respiratory Papillomatosis

Comprehensive multiomic characterization of human papillomavirus-driven recurrent respiratory papillomatosis reveals distinct molecular subtypes

Digital RNA Sequencing of Human Epidermal Keratinocytes Carrying Human Papillomavirus Type 16 E7

Profiling of VEGF Receptors and Immune Checkpoints in Recurrent Respiratory Papillomatosis

[Detection of Human Papillomavirus in the Upper Respiratory Tract in Children Without Recurrent Respiratory Papillomatosis].

Detection of HPV-2 and identification of novel mutations by whole genome sequencing from biopsies of two patients with multiple cutaneous horns.

Genome-Wide Profiling of Cervical RNA-Binding Proteins Identifies Human Papillomavirus Regulation of RNASEH2A Expression by Viral E7 and E2F1

Transcriptomic landscape of gene expression profiles and pathways in JORRP tumor tissues and HPV6/11 E6-E7-overexpressing HNSCC cell lines

Identification of Potential Prognostic Biomarkers in Vulval Squamous Cell Carcinoma Based on Human Papillomavirus Infection Status-Analysis of GSE183454

Study on Primary Culture of Juvenile Onset Recurrent Respiratory Papillomatosis Cells

VEGF as a Key Actor in Recurrent Respiratory Papillomatosis: A Narrative Review

Reduced NK Cell Cytotoxicity by Papillomatosis-Derived TGF-β Contributing to Low-Risk HPV Persistence in JORRP Patients

Transcriptome Sequencing Profiles of Cervical Cancer Tissues and SiHa Cells

Quantitative Detection of HPV DNA in Recurrentrespiratory Papillomatosis and Its Clinical Significance

Micrornas Are Biomarkers of Oncogenic Human Papillomavirus Infections

Recurrent respiratory papillomatosis: Immunological mechanisms involved in recurrence

Systemic bioinformatics analysis of recurrent aphthous stomatitis gene expression profiles.

Quantification and Functional Studies of Neutrophilic Cells Identifies Distinct Papilloma Phenotypes

Hpv-2 Isolates from Patients with Huge Verrucae Vulgaris Possess Stronger Promoter Activities

Characterization of HPV6/11-reactive T-cell subsets in papillomas of patients with juvenile-onset recurrent respiratory papillomatosis and identification of HPV11 E7-specific candidate TCR clonotypes